This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Centro de Imagem Diagnósticos allowed to participate in Brazil review of Fleury-Hermes Pardini deal

( September 26, 2022, 15:18 GMT | Official Statement) -- MLex Summary: Medical laboratory firm Centro de Imagem Diagnósticos has been allowed to participate in the Brazilian review of the combination of businesses of Fleury and Instituto Hermes Pardini, both of which operate in the healthcare market, according to a statement. As an interested third party, Centro de Imagem Diagnósticos can assist the Administrative Council for Economic Defense, or CADE, in its investigation and can appeal any eventual approval of the deal to the agency's Tribunal.OJ statement and CADE decision follow in Portuguese:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login